New vaccine aims to stop breast cancer recurrence in High-Risk patients

This early-phase study tested a personalized vaccine made from a patient's own immune cells, designed to target a protein called HER-2 found on some aggressive breast cancers. The goal was to see if the vaccine was safe and could train the immune system to prevent the cancer from returning. Fifteen women with high-risk HER-2 positive breast cancer who had completed standard treatments and had no current signs of cancer took part.